Handelsbanken Fonder AB Has $22.52 Million Holdings in argenx SE (NASDAQ:ARGX)

Handelsbanken Fonder AB lifted its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 13.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,050 shares of the company's stock after buying an additional 4,403 shares during the quarter. Handelsbanken Fonder AB owned about 0.06% of argenx worth $22,520,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Park Avenue Securities LLC raised its holdings in argenx by 6.4% during the 1st quarter. Park Avenue Securities LLC now owns 1,804 shares of the company's stock worth $1,068,000 after purchasing an additional 109 shares during the last quarter. Whipplewood Advisors LLC raised its holdings in argenx by 350.0% during the 1st quarter. Whipplewood Advisors LLC now owns 270 shares of the company's stock worth $160,000 after purchasing an additional 210 shares during the last quarter. GAMMA Investing LLC raised its holdings in argenx by 53,684.9% during the 1st quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock worth $802,200,000 after purchasing an additional 135,286 shares during the last quarter. Versant Capital Management Inc raised its holdings in argenx by 1,625.0% during the 1st quarter. Versant Capital Management Inc now owns 276 shares of the company's stock worth $163,000 after purchasing an additional 260 shares during the last quarter. Finally, Central Pacific Bank Trust Division raised its holdings in argenx by 24.8% during the 1st quarter. Central Pacific Bank Trust Division now owns 1,248 shares of the company's stock worth $739,000 after purchasing an additional 248 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Stock Down 1.5%

Shares of ARGX traded down $8.87 on Friday, hitting $577.89. The company's stock had a trading volume of 297,420 shares, compared to its average volume of 324,728. The firm's fifty day moving average price is $587.51 and its 200-day moving average price is $611.63. argenx SE has a fifty-two week low of $377.47 and a fifty-two week high of $678.21. The firm has a market capitalization of $35.29 billion, a price-to-earnings ratio of -656.69 and a beta of 0.39.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.26. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. As a group, equities analysts predict that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on ARGX shares. JMP Securities set a $699.00 price objective on argenx in a report on Wednesday, May 14th. William Blair restated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Citigroup reaffirmed a "buy" rating on shares of argenx in a research note on Wednesday, May 21st. Guggenheim lowered their price target on argenx from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, Baird R W raised argenx from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $709.18.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.